Lycera Corporation

Pharmacia & Upjohn Company

University of Michigan

Pah P&u LLC

Alexander Ross Hurd

Clarke Bentley Taylor

Peter Laurence Toogood

Gary D Glick

Chad A Van Huis

Michael R Barbachyn

Arthur Glenn Romero

Peng Zhou

Dennis Joseph McNamara

John R Palmer

Lisa Marie Thomasco

Debra Ann Sherry

J Craig Ruble

Paul Joseph Dobrowolski

Jian Wang

Chad A VanHuis

Matthew N Mattson

Gordon L Bundy

Donna Lee Romero

Donald James Skalitzky

Chad Alan Van Huis

Gary E Martin

Gordan L Bundy

Michael Robert Barbachyn

Dennis Joseph Mcnamara

John Raymond Palmer

The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit FF-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

[object Object]

The invention provides pyrazolyl guanidine compounds that inhibit FF-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

The invention provides indazole guanidine compounds that inhibit FF-ATPase, and methods of using indazole guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

The invention provides saturated acyl guanidine compounds that inhibit FF-ATPase, and methods of using saturated acyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

The invention provides pyridonyl guanidine compounds that inhibit FF-ATPase, and methods of using pyridonyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

The invention provides heterocyclic guanidine compounds that inhibit FF-ATPase, and methods of using heterocyclic guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.

The invention provides cycloalkyl guanidine compounds that inhibit FF-ATPase, and methods of using cyclalkyl guanidine compounds as therapeutic agents in therapy, such as treating an immune disorder, inflammatory condition, or cancer.

The invention provides 1,4-benzodiazepinone compounds, pharmaceutical compositions, and methods of treating autoimmune disorders, chronic inflammatory disorders, and hyperproliferative disorders. For example, the 1,4-benzodiazepinone compounds and pharmaceutical compositions are contemplated to be useful for treating rheumatoid arthritis, graft-versus-host disease, inflammatory bowel disease, and the like.

Benzodiazepinone compounds and methods of treatment using same

The present invention is directed to tricyclic tetrahydroquinoline compounds of formula I, and pharmaceutically acceptable salts thereof wherein the variables R, R, R, R, R, Rand X are as described herein and to pharmaceutical compositions thereof, that exhibit useful antibacterial activity against a wide range of human and veterinary pathogens.

Tricyclic tetrahydroquinoline antibacterial agents

The invention includes tetrahydroquinoline and related compounds of formula I and pharmaceutical compositions thereof, that exhibit useful antibacterial activity again a wide range of human and veterinary pathogens 

Growing community of inventors

Ann Arbor, MI, United States of America

Alexander Ross Hurd